Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Privigen

Known as: Venimmune 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
AIM A pharmacoeconomic analysis of direct costs on treatment with high dose intravenous immunoglobulins (IVIG) and plasmapheresis… Expand
Is this relevant?
2014
2014
IntroductionHemolysis is considered a class effect and a rare adverse event that can occur following therapy with human normal… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Activated clotting factor FXI (FXIa) has been postulated to play a significant role in thromboembolic events potentially… Expand
Is this relevant?
2014
2014
High dose intravenous immunoglobulin (IVIG) is an established treatment for various neuromuscular disorders. Recently, cases of… Expand
Is this relevant?
2013
2013
This prospective, multicenter, single‐arm, open‐label Phase III study aimed to evaluate the efficacy and safety of Privigen® (10… Expand
Is this relevant?
2011
2011
  • P & T : a peer-reviewed journal for formulary…
  • 2011
  • Corpus ID: 45340778
Ready-to-use 10% liquid IVIg Room temperature storage up to 36 months Sophisticated. First and only IVIg stabilized with proline… Expand
  • table 2
  • table 3
  • table 2
  • table 2
  • table 3
Is this relevant?
2009
2009
Abstract Intravenous immunoglobulin (IVIG) has become a mainstay of treatment for acute and chronic immune thrombocytopenic… Expand
Is this relevant?
2009
2009
The objective of this prospective, open-label, single-arm, Phase III study was to assess the efficacy and safety of Privigen… Expand
Is this relevant?
2009
2009
  • P & T : a peer-reviewed journal for formulary…
  • 2009
  • Corpus ID: 36625771
 
Is this relevant?
2009
2009
Background and Objectives  IgPro10 (Privigen©) is a new liquid intravenous immunoglobulin (IVIG) product that is formulated with… Expand
Is this relevant?